
CVS Health (CVS) Stock Forecast & Price Target
CVS Health (CVS) Analyst Ratings
Bulls say
CVS Health exhibited robust financial performance with Health Services revenue reaching $49.27 billion, reflecting a year-over-year growth of 11.6%, driven by operational efficiencies in its pharmacy drug mix and improved pricing strategies. Additionally, the company's Retail pharmacy segment reported $36.21 billion in revenue, marking an 11.7% year-over-year increase attributed to enhanced prescription volumes and market share growth. The strategic acquisition of Oak Street Health further strengthens CVS's position in primary care services, aligning well with its existing healthcare offerings and enabling potential synergies that support positive long-term growth projections.
Bears say
CVS Health's stock outlook is negatively impacted by projected challenges in achieving material earnings per share (EPS) growth due to headwinds in Medicare Advantage utilization, leading to an estimated FY26 EPS that is about 5% lower than current projections. The company also experienced a decline in segment adjusted operating income (AOI) by 7.0% year-over-year and a 1.8% drop in processed claims, indicating potential operational weaknesses. Additionally, the stock's valuation is expected to decrease to 9.8 times earnings, a level that reflects a significant reduction in market confidence compared to historical highs, further compounding the pressure from membership losses and rising regulatory scrutiny.
This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.
CVS Health (CVS) Analyst Forecast & Price Prediction
Start investing in CVS Health (CVS)
Order type
Buy in
Order amount
Est. shares
0 shares